Download the article in PDF format *** This article explores the risks associated with the irresponsible use of technology in the pharmaceutical industry, including scientific manipulation in drug trials, scientific misrepresentation through ghost-written publications, and abuse of technology through the misrepresentation of risks. The article highlights the negative impacts of these practices on patients, healthcare … Continue reading The Cost of Manipulation: The Irresponsible Abuse of Technological Opacity in the Pharmaceutical Industry
Download the article in PDF format *** On July 21, 2022, the United Kingdom’s Competition and Markets Authority (CMA) fined pharmaceutical companies Pfizer Inc. and Flynn Pharma Limited £63 million and £6 million respectively. The fines levied against these companies are the result of them abusing their market position as a means to overcharge the … Continue reading Pfizer/Flynn medicine monopoly and the NHS: A corporate exploitation of public resources in the United Kingdom
This article has been inspired by the discussion that took place during the international conference "Whistleblowers: Voices of Justice" that was held in London on the 10th of May 2019. The awarding of whistleblowers is a subject that has always presented two polarising views. On one hand, the view is that whistleblowers should be compensated … Continue reading The Competition and Markets Authority’s compensation campaign: Is the UK on the way to adopting an award system for corporate crime reporting?